Thus, it is highly possible that the hDMP1 gene is inactivated in a significant percentage of other types of human cancers, especially those that retain wild-type ARF and P53. Hence, ‘reactivation’ of the hDMP1 gene in cancer cells might be a feasible approach for novel cancer therapy since tumor cells often have one intact hDMP1 allele. This evidence concerns the gene CDKN2A and cancer.